Webinar – Clinical Experience of Using Nimotuzumab in Nasopharyngeal Cancer
Speaker: Dr. dr. Andhika Rachman, Sp.Pd-KHOM from MRCCC Siloam Hospital Indonesia
Similar Posts
ASCO 2013 : Nimotuzumab Abstracts
ByInnokeys
Professor Dirk Strumberg from Germany (center, in blue suit), the principal investigator of phase IIB/IIIA nimotuzumab clinical trial on pancreatic cancer, in…
New Marketing Authorization Approval in Myanmar for locally advanced unresectable or metastatic pancreatic cancer
ByInnokeys
New marketing authorization for indication locally advanced unresectable or metastatic pancreatic cancer is approved in Myanmar by the Myanmar FDA. This indication…
Webinar – Treatment Optimization in Locally Advanced & Metastatic Pancreatic Cancer-Tailored Patient Approach with Targeted Therapy
ByInnokeys
Prof. Dr. Dirk Strumberg, Oncologist in Marien Hospital Herne, Germany
New Marketing Authorization Approval in Cambodia for new indication of locally advanced unresectable or metastatic pancreatic cancer.
ByInnokeys
On 24 Sep 2019, Cambodia Ministry of Health approved new marketing authorization for indication locally advanced unresectable or metastatic pancreatic cancer for…
New publication shows benefit in patients with locally advanced or metastatic pancreatic cancer treated with nimotuzumab
ByInnokeys
New publication shows benefit in patients with locally advanced or metastatic pancreatic cancer treated with nimotuzumab in combination with gemcitabine. The…
YM BioSciences Reports Divestiture of Nimotuzumab Assets by CIMYM
ByInnokeys
MISSISSAUGA, ON, Dec. 3, 2012 /PRNewswire/ – YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM) today reported that CIMYM BioSciences Inc. has sold its assets relating to nimotuzumab to InnoKeys…